Stay updated with breaking news from Nasdaq Ctmx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BMO Capital Markets restated their market perform rating on shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) in a report published on Wednesday, Benzinga reports. BMO Capital Markets currently has a $3.25 target price on the biotechnology company’s stock. A number of other equities research analysts have also commented on CTMX. StockNews.com lowered CytomX Therapeutics […]
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase...
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,250,000 shares, a decline of 5.3% from the January 15th total of 1,320,000 shares. Based on an average daily trading volume, of 294,600 […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 981,600 shares, a decline of 26.7% from the November 30th total of 1,340,000 shares. Based on an average daily trading volume, of 197,200 […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) CEO Sean A. Mccarthy sold 13,551 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $1.38, for a total value of $18,700.38. Following the completion of the sale, the chief executive officer now […]